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Introduction: Acute Kidney Injury (AKI) is common in critical ill populations and its association with high short-term
mortality is well established. However, long-term risks of death and renal dysfunction are poorly understood and
few studies exclude patients with pre-existing renal disease, meaning outcome for de novo AKI has been difficult
to elicit. We aimed to compare the long-term risk of Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD)
and mortality in critically ill patients with and without severe de novo AKI.
Method: This cohort study was conducted between 2005 and 2011 in Swedish intensive care units (ICU). Data from
130134 adult patients listed on the Swedish intensive care register-database was linked with other national registries.
Patients with pre-existing CKD (4192) and ESRD (1389) were excluded, as were cases (26771) with incomplete data.
Patients were classified according to AKI exposure during ICU admission. Outcome in the de novo AKI group was
compared to the non-exposed (no-AKI) intensive care control group. Primary outcome was all-cause mortality.
Follow-up ranged from one to seven years (median 2.1 years). Secondary outcomes were incidence of CKD and ESRD
and median follow-up was 1.3 years.
Results: Of 97 782 patients, 5273 (5.4%) had de novo AKI. These patients had significantly higher crude mortality at
one (48.4% vs. 24.6%) and five years (61.8% vs. 39.1%) compared to the control group. The first 30% of deaths in AKI
patients occurred within 11 days of ICU admission whilst the 30-centile in the no-AKI group died by 748 days. CKD
was significantly more common in AKI survivors at one year (6.0% vs. 0.44%) than in no-AKI group (adjusted incidence
rate ratio (IRR) 7.6). AKI patients also had significantly higher rates of ESRD at one (2.0% vs. 0.08%) and at five years
(3.9% vs. 0.3%) than those in the comparison group (adjusted IRR 22.5).
Conclusion: This large cohort study demonstrated that de novo AKI is associated with increased short and long-term
risk of death. AKI is independently associated with increased risk of CKD and ESRD as compared to an ICU control
population. Severe de novo AKI survivors should be routinely followed-up and their renal function monitored.* Correspondence: claire.rimes-stigare@karolinska.se
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Acute kidney injury (AKI) is common amongst critically
ill patients and incidence is rising in synchrony with an
aging ICU population and their increasing comorbid
burden [1-4]. The extremely high in-hospital mortality
from AKI is well-established, but the extent to which sur-
vivors have a persistently increased risk of death, chronic
kidney disease (CKD) and end-stage renal disease (ESRD)
is uncertain [5-8].
Recent studies have demonstrated an association
between AKI and the risk of developing CKD and ESRD.
[9] Ponte and co-workers followed 187 AKI survivors and
found that over 50% of patients, without pre-existing
CKD, failed to recover their renal function [10]. A Danish
study found AKI patients on renal replacement therapy
(RRT) to have an 8.5% risk of developing ESRD, compared
with 0.1% for ICU controls, corresponding to a hazard ratio
(HR) of 105.6 [11]. Both CKD and ESRD are associated
with elevated risk of death and reduced quality of life
[12-17]. CKD is also specified by the World Health
Organisation as a risk multiplier for cardiovascular
disease, cancer, chronic respiratory disease, and diabetes
[18,19]. Understanding renal recovery in AKI survivors
is therefore essential in reducing long-term morbidity
and mortality.
For a number of reasons the extent to which critically
ill patients, with de novo AKI specifically, are at risk of
CKD and ESRD is unknown. First, many studies lack
pre-ICU data on CKD and hence, have not excluded
patients with CKD. Therefore, it is difficult to differentiate
the risks of developing CKD and ESRD in patients with
true de novo AKI from those with acute on chronic kidney
disease. Second, large studies have lacked ICU cohort
comparisons, often studying AKI in heterogeneous
populations such as hospital patients and therefore,
generalisation of findings to ICU populations is prob-
lematic. Third, in those studies with long-term follow
up of critically ill AKI survivors, mortality and ESRD but
not CKD have been followed. No previous large-magnitude
study has investigated CKD outcome in AKI survivors
after intensive care treatment. Last, national data for
outcome after AKI in Sweden have not previously been
described.
The Swedish health care system maintains national
databases of high quality and resolution, which offer the
unique opportunity to reliably obtain data on comorbidity
and outcome [20,21]. The Swedish Intensive Care Register
(SIR) with almost complete national ICU coverage
provided a population base and use of other national
registers allowed us to identify and exclude patients
with pre-existing CKD and ESRD. The present study
aimed to determine short- and long-term outcomes,
comparing risks of CKD, ESRD and mortality in patients
with and without severe de novo AKI.Methods
Study design
This cohort study used prospectively collected data
from SIR and other Swedish national health registries.
The Stockholm regional ethics committee (Regionala
etikprövningsnämnden i Stockholm) approved the study
and deemed informed consent unnecessary due to the
large scale and observational nature of the study. Data
were anonymized during crosslinking of registers.
Study cohort
The SIR provided the population base for this study and
data collected between January 2005 and January 2011
was extracted. We included the first admissions of all
eligible adult subjects. Patients with CKD and ESRD
prior to admission and those under 18 years, as well as
those with incomplete records were excluded. Records
were considered incomplete if International Classification
of Diseases Version-10 codes (ICD-10), intervention
codes and scoring systems were all absent because
AKI classification of these patients was not possible.
SIR was established in 2001 and by 2005 was receiving
data on ICU admissions from 41 of the then 88 Swedish
ICUs. Recruitment has increased and SIR included 91%
of all patients admitted to Swedish ICUs in 2011 [22].
Information is submitted from ICUs in district, county
and tertiary referral centres and includes data from
cardiothoracic, neurosurgical and burns injury units
as well as general ICUs.
Mandatory SIR data includes patient characteristics
and administrative details of each ICU admission. These
data are complete. Submission of other variables is optional
and these data are sometimes absent. Non-mandatory data
include registration of interventions (for example, invasive
ventilation or RRT), surgical status, complications and
disease-severity scoring systems. Laboratory data were
obtained from these scoring systems; premorbid laboratory
data are not collated. Further details of SIR are found in
Additional file 1.
SIR-data were cross-matched using the unique 10-digit
Swedish identity number, assigned after birth or immigra-
tion with the following national registers [23]: 1) Swedish
cause of death register, used to obtain details of all-cause
mortality. This includes the deaths of all Swedish citizens
and residents with a national identification number. This
register is considered to be a very reliable source of data
with over 99% of all deaths reported to it [24]; 2) National
Patient Register (NPR) from which the cohort’s
premorbid status was ascertained and classified ac-
cording to the Charlson comorbidity index [25]. Pa-
tients with pre-existing renal disease (according to the
Charlson definitions) were identified here, as were
subjects developing CKD (ICD-10 codes N18 and N19)
post ICU admission and 3) Swedish Renal Register (SRR)
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ICU admission.
NPR is a mandatory register comprising the in- and
outpatient registers; the ICD-10 diagnosis codes recorded
here are used as the internal debit system within the
Swedish health care system. The inpatient register contains
all hospital discharges in Sweden, and complete coverage
has been achieved since 1987 [26]. Outpatient register
validation in 2011 indicated that 77% of all outpatient
episodes were recorded, and private healthcare contacts
accounted for the majority of omissions [27,28]. The SRR
includes details of all individuals receiving treatment for
ESRD. The database records the start and finish date for all
patients receiving chronic haemodialysis or peritoneal
dialysis and those who receive renal transplants. There are
around 3,700 patients receiving dialysis in Sweden at any
point in time. Our primary outcome measure was one-year
mortality. Secondary endpoints were CKD and ESRD.
Definitions
Premorbid creatinine levels or glomerular filtration rate
(GFR) estimates were not available for this national
cohort. Patients were considered to have de novo AKI
(referred to as AKI from this point onwards) if at least
one of the following criteria was fulfilled: 1) intermittent
haemodialysis (IHD) or continuous renal replacement
therapy (CRRT) was reported in SIR; 2) diagnosis of
acute renal failure was recorded within the Acute
Physiology and Chronic Health Evaluation (APACHE)-II
score, defined as creatinine increased by more than 1.5
times from baseline, with urine output <410 ml in 24
hours; 3) the diagnosis code, acute kidney failure N17
in ICD10, was assigned at discharge, and 4) A serum
creatinine >354 μmol/L (Kidney Disease Improving
Global Outcomes (KDIGO) grade 3) was recorded on
admission in APACHE-II, Simplified Acute Physiology
Score (SAPS)-II or SAPS-III scoring systems. The
ICU comparison cohort that did not fulfil these criteria,
and did not have CKD or ESRD prior to ICU admission,
was referred to as the no-AKI group.
CKD post ICU was considered present if ICD-10 codes
N18 or N19 were assigned (NPR) at least 3 months after
a patient’s ICU admission. ESRD post ICU was sought in
SRR in survivors. Data from the Swedish cause of death
register were available until 31 December 2011 and the
maximum follow up for the primary outcome was 7
years. Data from other national registers were available
until 31 December 2010 and therefore, secondary analysis
was performed up to this date with a maximum follow up
of 6 years.
Statistical analysis
We report continuous data as median with the IQR.
Categorical data are expressed as count and percentage.The Mann-Whitney test was used to compare distributions
of continuous variables at baseline between AKI and non-
AKI patients. Fisher’s exact test was used to compare
prevalence of comorbidities between groups. A two-sided
P-value <0.05 was considered significant.
Primary analysis
We considered time from ICU admission to death or
end of follow up (31 December 2011) for death or 31
December 2010 for secondary analysis or combined
analysis), whichever occurred first. Information on emigra-
tion was unavailable. Survival curves were estimated by the
Kaplan-Meier method and the log-rank test was used to
verify equality of survivor functions between subgroups.
We tested for proportionality of survival curves using
Schoenfeld residuals and found evidence of non-
proportionality; proportional hazard regression was
therefore inappropriate and we instead used Poisson
regression and present incidence rate ratios (IRRs).
Multivariate analysis
Potential confounders were considered on the basis of
prior knowledge of AKI and on whether addition of the
covariates to the models changed estimates of relative
risk by >10% [29]. We selected and tested age, sex,
SAPS-III score (the scoring system most often recorded),
acute surgery and the Charlson comorbidity groups as
potential confounders and adjusted for these in our
sensitivity analysis of subgroups. We present two models
of multivariate analysis.
Survival percentiles
Laplace regression was used to obtain the number of
days of survival for the fifth to the thirtieth centiles of
the AKI and non-AKI groups.
Secondary analysis
This was performed in a similar manner to survival
analysis. Time from admission to event (CKD or
ESRD) was considered and censoring occurring at the
point of ESRD in the case of CKD, or death or end
of follow up whichever occurred first. A univariate
model for the cumulative risk of developing either CKD,
ESRD or of dying at any time point was constructed by
considering the different endpoints of CKD, ESRD and
death as competing events (Additional file 1: Figure S1).
All analysis was performed using Stata version 12
(StataCorp LP, College Station, TX, USA).
Results
The SIR included data on first admissions of 130,134
adult patients between January 2005 and January 2011.
A flowchart detailing case exclusion is found in Figure 1.
A total of 97,782 patients were included in the final
Figure 1 Flowchart of study population. SIR, Swedish intensive care
register; AKI, acute kidney injury; CKD, chronic kidney disease; ESRD,
end-stage renal disease.
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excluded due to insufficient data are presented in
Additional file 1: Table S1. Median follow up for primary
outcome was 2.1 years. Whilst for secondary outcome it
was 1.3 years.
Of 97,782 patients 5,273 (5.4%) were identified as having
AKI. The characteristics of patients with and without AKI
are presented in Table 1. AKI patients were older (median
67.9 versus 59.3 years, P <0.001), had longer ICU length
of stay (LOS) and were more often men (60.4% versus
56.4%, P <0.001). The AKI group had higher potassium
(median 4.7 versus 4.1 mmol/l, P <0.001) and lower
sodium (median 133 compared to 136 mmol/l, P <0.001)
than controls. AKI patients were more acidotic
(median pH 7.29 versus 7.36, P <0.001) with lower serum
bicarbonate values at admission. APACHE II, SAPS-II and
SAPS-III scores were all significantly higher in AKI patients.
Interventions were under-reported, but AKI patients
differed from controls by having higher rates of invasive
ventilation (18.9 versus 7.7%, P <0.001) and emergency
surgery (12.6 versus 7.8%, P <0.001).
Compared with the no-AKI group, patients with
AKI had significantly more comorbidities except for
dementia, and higher Charlson scores (1.78 versus
2.65, P <0.001). The proportion of patients with car-
diovascular disease was higher in the AKI group, with
18.7% incidence of myocardial infarction and 25%
incidence of congestive cardiac disease, compared to
12.9% and 13.5%, respectively, in the non-AKI patients.
Diabetes was significantly more common in those
with AKI (uncomplicated 26.3% versus 14.2%), likewise
the proportion of AKI patients with liver disease and
cancer was significantly higher than in the corresponding
no-AKI group.Primary outcome
During follow up 34,473 patients (35.3%) died. Rates of
all-cause mortality were higher in patients with AKI,
0.387 deaths per person/year compared to 0.134 in the
non-AKI population with a mortality rate ratio (MRR) of
2.87. This diminished but remained elevated in both
adjusted models presented (2.14 in model 1 and 1.15
in model 2, Table 2).
Mortality rates were highest during the first days after
admission. The AKI group had a significantly higher
mortality rate than the comparison no-AKI group as
illustrated in Table 2. Crude survival for the 5th to 30th
centiles is presented in Table 3. Notably 5% of all pa-
tients died within one day of ICU admission. Twenty
percent of AKI-patients were dead within 4 days of
admission and the first 20% of deaths in the non-renal
disease group occurred by 118 days. In the no-AKI
group 30% had died by day 748 (2 years). In contrast
30% of patients in the AKI group had died within 11
days. A multivariate model (Additional file 1: Table S4)
demonstrates how survival centiles differ depending on
covariate patterns.
Kaplan Meier estimates showed 90-day survival in
the AKI group to be 56.5% versus 80.6% in no-AKI
comparison cohort (Figure 2A). One-year survival was
51.3% in those with severe AKI and 75.4% in the
comparison no-AKI group. Five-year survival decreased to
38.2% for AKI-patients and 60.8% for the no-AKI cohort
(Additional file 1: Table S2).
Secondary outcomes
Incidence of CKD was significantly higher in the AKI
group (6.0% at one year and 10.5% at 5 years) compared
to controls (0.44% at 1 year and 1.8% at 5 years) with a
crude IRR of 10.3 and an adjusted IRR of 7.6 (Table 4).
The risk of ESRD after ICU admission was low but
significantly higher in the AKI group. The incidence rate
in AKI patients was 0.0125 events per person-year
compared to 0.0007 in the no-AKI cohort. The crude IRR
was 18.6 (13.7, 25.2) and 22.5 (12.9, 39.1) after adjustment.
The incidence of ESRD in the AKI group was 2.0% at 1 year
increasing to 3.9% at 5 years, whereas in the the no-AKI
group the 1-year and 5-year incidence of ESRD was 0.08
and 0.3%, respectively (Additional file 1: Table S3).
Discussion
In the largest cohort of critically ill patients to examine
the risk of CKD, ESRD and long-term mortality after de
novo AKI, we showed that de novo AKI is independently
associated with increased mortality and risks of ESRD
and CKD. We demonstrated that patients with de novo
AKI had 2.7 higher risk of dying, seven-fold risk of
developing CKD and twenty-two times higher risk of
developing ESRD than the comparison non-AKI cohort.
Table 1 Baseline characteristics of the study patients
Baseline characteristics No acute kidney injury (n = 92,509) Acute kidney injury (n = 5,273) P-value
Mean age, years 59.3 (19.6) 67.9 (14.2) <0.001
Median age, years 63 (45 to 75) 70 (61 to 78)
Length of ICU stay, hours 23 (12 to 53) 68 (26 to 189) <0.001
Women 40411 (43.6) 2086 (39.6) <0.001
Number of admissions per patient, mean (SD) 1.31 (0.89) 1.29 (0.74) 0.19
Number of admissions per patient, median (IQR) 1 (1 to 1) 1 (1 to 1)
Highest potassium, mmol/L 4.1 (3.9 to 4.5) 4.7 (4.1 to 5.5) <0.001
Number 16069 1605
Highest sodium, mmol/L 139 (136 to 142) 137 (134 to 141) <0.001
Number 16121 279
Lowest sodium, mmol/L 136 (133 to 139) 133 (130 to 137) <0.001
Number 16121 1604
Highest bilirubin, μmol/L 10 (6 to 17) 14 (8 to 26) <0.001
Number 16863 1768
Lowest arterial pH 7.36 (7.30 to 7.41) 7.29 (7.19 to 7.38) <0.001
Number 40449 3968
Lowest bicarbonate, mmol/L 23 (20 to 25) 18 (14 to 22) <0.001
Number 3662 593
Maximum creatinine (μmol/L) 80 (63 to 105) 254 (164 to 422) <0.001
Number 47441 4076
Maximum urea (mmol/L) 6.7 (4.3 to 10.1) 17.5 (11 to 26) <0.001
Number 2717 532
Lowest thrombocyte count, x 109/L 230 (170 to 296) 199 (123 to 291) <0.001
Number 32586 2695
Apache II score 14 (8 to 20) 25 (20 to 32) <0.001
Number 17231 1620
SAPS II score 25 (0 to 41) 55 (42 to 70) <0.001
Number 15376 764
SAPS III score 52 (43 to 63) 68 (59 to 77) <0.001
Number 18326 1437
Intervention, number (%)a
Invasive mechanical ventilation, numbera 7155 (7.7) 994 (18.9) <0.001
Acute surgerya 7282 (7.8) 662 (12.6) <0.001
Elective surgerya 5237 (5.7) 295 (5.6) 1.0
Charlson comorbidity score, meanb (SD) 1.78 (2.2) 2.64 (2.5) <0.001
Comorbidity, number (%)
Myocardial infarction 11896 (12.9) 986 (18) <0.001
Congestive cardiac failure 12521 (13.5) 1324 (25.1) <0.001
Peripheral vascular disease 8921 (9.6) 704 (13.4) <0.001
Cerebrovascular disease 15658 (16.9) 808 (15.3) <0.001
Dementia 1840(2.0) 99(1.9) 0.612
Chronic obstructive pulmonary disease 12999 (14.1) 808 (15.3) 0.010
Rheumatological disease 3311 (3.6) 269 (5.1) <0.001
Peptic ulcer disease 5693 (6.2) 423(8.0) <0.001
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Table 1 Baseline characteristics of the study patients (Continued)
Cancer 15726 (17.0) 1262 (24.0) <0.001
Metastatic disease 1918 (3.6) 304 (4.7) <0.001
Mild liver disease 45021 (4.9) 369(7.0) <0.001
Moderate or severe liver disease 3319 (2.1) 249 (5.8) <0.001
Uncomplicated diabetes 13168 (14.2) 1372 (26.2) <0.001
Diabetes with complications 4660 (5.0) 523 (9.9) <0.001
Paraplegia 1787 (1.9) 90 (1.7) 0.287
HIV 125 (0.14) 4 (0.08) 0.328
Values are median (IQR) or n (%). if not otherwise stated. Information on laboratory data were obtained from the severity scorings systems APACHE II, SAPS II and
SAPS III. APACHE and SAPS2 record the highest or lowest values recorded during the first 24 hours of ICU admission, and SAPS3 records values from 1 hour
before until 1 hour after ICU admission. Values for scoring systems were not available in all patients; number denotes the number of patients in which this
information was recorded. aIntervention codes were also under-reported and therefore the number of patients in whom these data were available is detailed in
the table. Reporting of all other baseline characteristics is complete. bCharlson score is not age-adjusted. APACHE, acute physiology and chronic health evaluation;
SAPS, simplified applied physiology score.
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aimed to detect patients with severe de novo AKI
(described in Methods). These criteria included creatinine
levels in line with classification of risk, injury, failure, loss,
end-stage renal failure (RIFLE)-3, or AKI requiring dialysis,
but also included the diagnoses of acute renal failure in
APACHE II and acute kidney injury in ICD10, which could
potentially have identified patients with somewhat milder
AKI. However, diagnoses were generally under-reported
and we suggest that cases of severe disease were more likely
to have been recorded. We therefore believe that our co-
hort largely consists of cases of severe de novo AKI.
Our findings are largely consistent with other Scandi-
navian studies, investigating outcome after severe AKI.
The Swedish Intensive Care Nephrology Group (SWING)
study, conducted in 32 Swedish ICUs between 1995 and
2004, recorded 90-day mortality of 50.6% amongst patients
who received CRRT [30]. This is somewhat higher than in
our current study (43.5%). The FINNAKI study recorded
90-day mortality of 39% in patients classified as Acute
Kidney Injury Network (AKIN) and KDIGO stage 3 [31].
The differing mortality may partly be explained by our AKI
cohort being somewhat older (median age 68.3 versus 66
years) with higher SAPS-II scores (53.7 versus 43) during
the same study period of 2006 to 2008 (not shown).
Gammelager and colleagues in a Danish ICU-cohort
recorded 90-day mortality in patients with RIFLE-F ofTable 2 Multivariate regression analysis
A. Multivariate poisson regression analysis showing the association bet
Group Number Deaths Person-years Mortality rate
person-year (9
No AKI 92,509 31,530 2.3 x 105 0.135 (0.134, 0.1
AKI 5,273 2,943 7.6 x 103 0.387 (0.374, 0.4
aModel 1: adjusted for age, gender, myocardial infarction and diabetes mellitus with
physiology score-III, myocardial infarction, cerebrovascular disease, diabetes mellitu
AKI, acute kidney Injury; MRR, mortality rate ratio.54.7%, and one-year mortality in the Laeknabladids
Icelandic study was 48% [11,32].
International studies reporting long-term mortality for
severe AKI vary from 48 to 76% at 1 year, to 84% at 5
years [7,33-35]. Recently, investigators in the RENAL-trial
reported a total mortality rate of 63% in extended
follow -up (up to 4 years) of 90-day survivors of AKI
requiring dialysis [36]. This is slightly higher than in
our Swedish cohort (58.1%).
In our current study the incidence of ESRD was lower
than in the earlier Swedish SWING study (8.3% in those
who had received CRRT) despite all-cause mortality
being lower. However, patients with CKD were excluded
from the present study. This result may indicate that
treatment has improved since the SWING-study a
decade ago [30]. The incidence of ESRD in SIR is lower
than in the Gammelagers Danish cohort (8.5% at 6
months) and interestingly lower than in FINNAKI where
11.5% of survivors were dialysis-dependent [11,37]. This
could reflect competing risks of death and ESRD. The
Post RENAL study with a mean follow up of 42 months
reported ESRD incidence of between 5.1 and 5.8%
(depending on CRRT intensity) [36]. The Pannu Canadian
cohort study of patients with KDIGO grade 2 or
more recorded a very low incidence (2.1%) of dialysis
dependence in survivors up to 34 months; these findings









37) 1 1 1
02) 2.87 (2.76, 2.97) 2.14 (2.06, 2.22) 1.15 (1.09, 1.21)
complications. bModel 2: adjusted for age, gender, simplified acute
s with complications, moderate to severe liver disease, cancer and dementia.
Table 3 Crude survival centiles according to AKI status
Group Crude Survival (days) for each given centile (95% CI)
5th 10th 20th 30th
No AKI 1.0 5.9 118.5 748
AKI 0.63 1 4 11
AKI, acute kidney Injury; MRR, mortality rate ratio.
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vivors than in the non-AKI group. These findings are con-
sistent with other studies [9,10,39]. Renal dysfunction is
common after AKI and CKD has been shown to occur in
between 20 and 40% of patients [1,40,41]. As routine sur-
veillance of renal function in AKI survivors is lacking in
Sweden, the true extent of renal dysfunction in this group
has been unknown [42]. A recent study found that follow
up by nephrologists improved all-cause mortality in survi-
vors with severe AKI [43]. Given the known association of
renal dysfunction with reduced quality of life and increased
risk of death, our findings underline the importance of
post-ICU renal function surveillance and optimisation.
This study has limitations. First, under-reporting of
diagnosis codes and particularly interventions in SIR
hindered our ability to identify all severe AKI patients
and to describe AKI incidence in this population. Under-
reporting is a problem inherent in register research and
particularly in cohorts of this magnitude. We suggest that
although our method may not have exhaustively identified
all patients with AKI, those assigned to the AKI group
were correctly classified. The statistically significant differ-
ence in outcomes observed between groups and the simi-
larity of our findings to other studies suggest that the
identification process was largely successful.
Individuals excluded due to lack of sufficient data were
younger, with lower comorbidity and disease severity
scores and had shorter LOS than the study cohort. ICU
admission generally occurred early during the study and
was more likely to have been to a smaller ICU. Excluded
subjects may represent a healthier group, with lowerA B
Figure 2 Estimates of survival, end-stage renal disease (ESRD) and chronic
acute kidney injury (AKI) and patients with no AKI. Kaplan-Meier curves for
observed at 90 days (B) reflects that most diagnoses of ESRD were made a
severely reduced glomerular filtration and dialysis dependence.incidence of AKI. Higher turnover of healthier patients
and initiation issues may explain failure to fully register
data. Sicker individuals with longer LOS, like AKI-patients,
may have been more conscientiously reported. Excluded
patients had significantly lower mortality rates than the
population studied. Their exclusion should have the effect
of reducing differences between groups in the final cohort
towards the null. Still, significant differences between AKI
and non-AKI groups were observed.
The reliability of the NPR allowed us to identify
patients previously diagnosed with CKD, however, base-
line creatinine or GFR measurements were not available
for the cohort and it is possible that some patients had
undiagnosed CKD prior to admission to ICU.
Scoring systems are routinely presented in regression
models and we include SAPS-III in one of our models
for completeness. However creatinine is one of the vari-
ables used to derive the SAPS-score, which itself is used
to classify patients into AKI and non-AKI groups. We
suggest that use of SAPS-III as a covariate without re-
moval of renal points could lead to over-adjustment.
Furthermore, covariates such as age, acute surgery and
malignancy are also common to SAPS-III and may com-
pound issues of over-adjustment.
Although the maximum follow up was 7 years and 6
years for primary and secondary outcomes, respectively,
complete follow up was only available for 1 year. It
should therefore be noted that figures for 5-year survival
and prevalence of ESRD and CKD are estimates.
Finally, data on emigration were unavailable, there-
fore, censoring due to emigration is not included in
our regression analysis. Given the health status and
median age of our cohort, we suspect that very few
people are likely to have emigrated during the follow-
up period and results are unlikely to be significantly
affected.
The major strengths of our study are its magnitude,
combined with the high coverage of the national inten-
sive care cohort in the SIR database. Furthermore, theC
kidney disease (CKD) three years after ICU admission in patients with
cumulative mortality (A), ESRD (B), and CKD (C). The steep drop
ccording to diagnostic guidelines after three months of persistent
Table 4 Multivariate poisson regression for secondary outcomes
Multivariate poisson regression analysis







No AKI 92,509 649 1.7 × 105 0.0038 (0.0035, 0.0041) 1 1
AKI 5,273 193 4.9 × 103 0.0340 (0.0341, 0.0452) 10.3 (8.8, 12.1) 7.6 (5.5, 10.4)
B. ESRD
No AKI 92,509 116 1.7 × 105 0.0007 (0.0006, 0.0008) 1 1
AKI 5,273 65 5.2 × 103 0.0125 (0.0098, 0.0160) 18.6 (13.7, 25.2) 22.5 (12.9, 39.1)
aAdjusted for simplified applied physiology score version III, age, gender and diabetes. CKD, chronic kidney disease; ESRD, end-stage renal disease; AKI, acute
kidney injury; IR, incidence rate; IRR, incidence rate ratio.
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describe the long-term outcome in this large cohort with
a uniquely high degree of internal validity. The cohort
size permitted us to establish an ICU control population
for comparison, which only a handful of previous studies
have been able to do. This may make the external
validity of our results higher than that of most of the
previous studies.
Significance
Our results are unique because in a large cohort, they
demonstrate that mortality and rates of ESRD are
relatively low compared to other contemporary studies
and with an earlier Swedish study. This could reflect
improvements in treatment of AKI. Our finding of an
association between AKI and the risk of developing
CKD has implications for clinical practice and ought
to prompt routine nephrology follow up of these indi-
viduals. Using this database we intend to further
investigate how outcomes for patients with pre-existing
CKD and ESRD differ from those with de novo AKI
and no AKI.
Conclusion
This large Swedish cohort study has demonstrated that
ICU patients with de novo AKI have elevated risk of
death, chronic and end-stage renal disease as compared
to an ICU control population. These findings emphasize
the importance of monitoring and optimisation of renal
function in survivors recovering from AKI. The total risks
of death and ESRD are lower during this period as com-
pared to a Swedish study conducted during the preceding
decade and may indicate a temporal improvement in AKI
management.
Key messages
 AKI in critically ill patients is associated with an
increased long-term risk of death. AKI survivors have a seven-fold increased risk of
developing chronic kidney disease compared to
non-AKI ICU patients.
 AKI survivors have twenty-two times increased risk
of developing end-stage kidney disease compared to
non-AKI ICU patients.
 Risk of death and ESRD after AKI may have
improved over the last decade.Additional file
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